IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells.
about
Role of the tumor microenvironment in mature B-cell lymphoid malignanciesChronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted AgentsPharmacological targeting of PI3K isoforms as a therapeutic strategy in chronic lymphocytic leukaemiaIdelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular LymphomaTargeted therapies in CLL: mechanisms of resistance and strategies for managementTargeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisibSecondary mutations as mediators of resistance to targeted therapy in leukemiaIbrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumabTargeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms.The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomasTargeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection.Factors involved in CLL pathogenesis and cell survival are disrupted by differentiation of CLL B-cells into antibody-secreting cells.Targeted therapy for chronic lymphocytic leukemia: current status and future directions.Emerging immunological drugs for chronic lymphocytic leukemia.Pharmacodynamic considerations of small molecule targeted therapy for treating B-cell malignancies in the elderly.Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.New drug discovery approaches targeting recurrent mutations in chronic lymphocytic leukemia.Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cellsTargeting the mTOR Pathway in Leukemia.Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets.Paving the way for new agents; is standard chemotherapy part of the treatment paradigm for chronic lymphocytic leukemia in the future?Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.How I manage ibrutinib-refractory chronic lymphocytic leukemia.Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia.The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.Recent therapeutic advances in chronic lymphocytic leukemia.Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia.Combination therapy with the type II anti-CD20 antibody obinutuzumab.Distinct roles for phosphoinositide 3-kinases γ and δ in malignant B cell migration.Antitumor effects of duvelisib on Epstein-Barr virus-associated lymphoma cells.Identification of potential ibrutinib combinations in hematological malignancies using a combination high-throughput screen.Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 studyCopanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib
P2860
Q26748775-BA63E1E2-C5F5-4113-BD0B-2FB0EFEFA19BQ26764833-1818EF4A-97FD-4BB7-BE05-1D46E87F3233Q26779129-AC9E02E5-A6A2-4851-91FA-7702C053EC93Q26865645-E4E2B40B-D17F-4348-8326-F639E3DD2197Q27002528-9EBB6330-35B9-4FBA-B015-AEC495185DC5Q27025812-D03513B2-D692-4A82-8176-925A2C985B62Q28087213-C10FB4FB-3A50-45AE-987B-AC5099A8DEBAQ30252869-1F9E65DB-1FC6-4FF5-B2FB-7665015A41A0Q35076449-1AEBE218-7C26-443B-A112-76B51FFFED54Q35727453-6691D890-76DE-458B-81B7-AAAAEC8F4ECEQ36021849-D939A2B1-55FA-4E6B-9000-EDCCB5910422Q37058203-EF7C0263-9FCD-4093-BFD9-BBE13DF7D439Q37457673-5FAA3C1A-AC86-4CD9-8E1B-D507E6B179F5Q38298483-3EE2A3FA-F79F-4C78-A294-799BD7043592Q38331701-794BC76F-F7AB-407A-880D-75AAD2EEC622Q38543771-DB5A27EE-F9C9-4F76-BD41-9985A0FBB749Q38544216-4D6F17A0-695A-4529-9BD3-6673F9B24FEFQ38550810-663BDB4C-D0AF-4428-81E8-F945758F645CQ38646974-AC53117E-B8F1-471D-B638-F687ABD63BBAQ38716411-485BCEA0-FD53-486F-8EBB-2E3B600E7015Q38790630-B9AFA317-3012-4828-B81E-BA8B4A3B6588Q38819164-A76D3401-1259-4CD8-9B4C-910FE11DFFB9Q38851368-1181D807-7E69-44E5-8914-3C67B2B1939DQ38882332-81B1086D-5F89-44CA-B8A4-EB3BD866A769Q39016282-E03AE8C2-4EFC-4918-8A05-1859F18D160AQ39226787-4A5244B1-CFB9-42DB-B741-9355ED5F71D2Q40575812-84727F9B-1626-4C7D-B7B9-B80862C5270BQ41994564-B874C546-AFD5-4440-BF89-0C4795B0729AQ46318389-DD500BEE-CD45-4ABB-8E8C-0968DA044B42Q47754054-EC46667A-885A-4635-BCFC-96B88E6C2668Q47898168-53F0D862-474E-4AC1-BE92-AC678E337129Q51738230-0CB4A630-822A-4095-8F1D-608F7A3CA90FQ52664561-AE20CE75-BFB0-4424-B450-143D94E8598CQ54990441-231A4C23-21E6-4E69-AE92-D1828384850DQ58697794-3D733EA3-8A3F-40CF-80AF-799295F0C069Q58729853-48E54D80-D7B9-48DA-80B6-62A1382EE6B5
P2860
IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
IPI-145 antagonizes intrinsic ...... ic lymphocytic leukemia cells.
@ast
IPI-145 antagonizes intrinsic ...... ic lymphocytic leukemia cells.
@en
IPI-145 antagonizes intrinsic ...... ic lymphocytic leukemia cells.
@nl
type
label
IPI-145 antagonizes intrinsic ...... ic lymphocytic leukemia cells.
@ast
IPI-145 antagonizes intrinsic ...... ic lymphocytic leukemia cells.
@en
IPI-145 antagonizes intrinsic ...... ic lymphocytic leukemia cells.
@nl
prefLabel
IPI-145 antagonizes intrinsic ...... ic lymphocytic leukemia cells.
@ast
IPI-145 antagonizes intrinsic ...... ic lymphocytic leukemia cells.
@en
IPI-145 antagonizes intrinsic ...... ic lymphocytic leukemia cells.
@nl
P2093
P2860
P1433
P1476
IPI-145 antagonizes intrinsic ...... ic lymphocytic leukemia cells.
@en
P2093
Amy J Johnson
Amy Lehman
Daphne Guinn
Jason A Dubovsky
Jeffery Kutok
Jennifer A Woyach
Shuai Dong
Yiming Zhong
P2860
P304
P356
10.1182/BLOOD-2014-07-587279
P407
P50
P577
2014-09-25T00:00:00Z